The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Construction
  • Automotive
  • Technology
  • Music
  • Arts

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children
The PennZone/10124083

Trending...
  • Torch Entertainment Presents The Frozen Zoo
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- In a multi-institutional study, researchers in the Developmental-Behavioral Pediatrics Research Network (DBPNet), led by Children's Hospital of Philadelphia (CHOP), have conducted the first and largest analysis to date comparing the effectiveness and side effects of stimulants like methylphenidate (Ritalin) and alpha-adrenergic agonists like guanfacine (Tenex) in preschool-age children. The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors. The retrospective study was published today in JAMA.

"This is really the first study of any size to report on the frequency of improvement and side effects of drugs like guanfacine in preschool-age children," said senior author Nathan J. Blum, MD, Chief of the Division of Developmental and Behavioral Pediatrics at CHOP. "While this study confirms that clinicians are using drugs like guanfacine in preschoolers and that those drugs may be useful in some children, the research also strongly suggests we need future research to look in a rigorous way at the use of alpha-adrenergic agonists in this age group."

More on The PennZone
  • NorthSky Celebrates One-Year Anniversary
  • Free At Last Bail Bonds Gives Back Through Major Holiday Food Distribution Efforts Across Metro Atlanta
  • Discover Elevated Living - Preview the Stunning New Townhome Collection
  • TownePlace Suites Prescott Valley, AZ Opens
  • SIX7 Introduces Olfactory Neurodesign™ — The First Fragrance System Engineered to Influence Emotion, Memory, and Desire at the Neural Level

To assess the use, effectiveness, and side effects of stimulants and alpha-adrenergic agonists in preschoolers, the researchers reviewed electronic health records of 497 children seen at seven DBPNet outpatient developmental-behavioral pediatric practices between January 2013 and July 2017. Children included in the study were under the age of 6 when first treated with an alpha-adrenergic agonist or stimulant.

The researchers found that 175 children (35%) were prescribed an alpha-adrenergic agonist like guanfacine, while 322 children (65%) were prescribed a stimulant like methylphenidate (Ritalin). Although both groups reported improvement in symptoms, the benefit was slightly larger among those prescribed stimulants (78% vs. 66%).

However, in terms of side effects, patients taking alpha-adrenergic agonists reported fewer side effects than those taking stimulants, with lower rates of moodiness/irritability (50% vs. 29%), appetite suppression (38% vs. 7%), and difficulty sleeping (21% vs. 11%). The only side effect that was more common for those taking alpha-adrenergic agonists than those taking stimulants was daytime sleepiness (38% vs. 3%).

The researchers also found children younger than 4 years old who were prescribed a drug like guanfacine were likely to continue using the medication for longer than if they were prescribed a stimulant. In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant. For those ages 4 to 5, there was no significant difference between medications.

"Although the retrospective nature of our study means we weren't able to tell why patients stopped a given medication rather than continued with it, these data support potentially tailoring medication based on a child's age, among other personal factors that might influence medication decisions," Blum said. "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient."

More on The PennZone
  • GetKuwa emerging as GCC's #1 trusted online supplement marketplace as shoppers across UAE, Saudi Arabia, Kuwait, Qatar & Oman seek authenticity
  • Uk Financial Ltd Provides Investors Of Maya Preferred & Mayacat Instructions For Upcoming First Ever Listing Of Both Erc-3643 "SEC-Ready" Tokens
  • Kaufman Development and Daniel Kaufman Ventures Announce Strategic Expansion Into Data Centers and AI Infrastructure Across the United States
  • Bent Danholm Lists Modern Lakefront Estate in Winter Garden's Twinwaters Community
  • Operational Agility in High Demand: FOCUS Expands to Serve a Changing Insurance Market

Other institutions involved in the study include Boston Children's Hospital; the Perelman School of Medicine at University of Pennsylvania; University of Oklahoma Health Sciences Center; Keck School of Medicine at University of Southern California, Los Angeles; Children's Hospital Los Angeles; Children's Hospital Colorado; Medical University of South Carolina; Stanford University; and Atrium Health.

Harstad et al. "α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder," JAMA, online May 4, 2021, DOI: 10.1001/jama.2021.6118

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Camillia Travia
Children's Hospital of Philadelphia
(425) 492-5007
[email protected]

SOURCE Children's Hospital of Philadelphia

Related Links

http://www.chop.edu
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Gramercy Tech Launches StoryStream
  • Entrigue Magazine LLC Announces Strategic Media Partnership with Reewind Network LLC
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States
  • Winzele: A Trusted Isolation Transformer Manufacturer
  • Luxury Mediterranean Estate in Gotha Sells for $1.52 Million, Closing $45,000 Over Asking
  • ZEELOOL's Black Friday Sale Starts Early with Up to 80% Off Frames
  • UV Weathering Test Chamber vs Xenon Arc Test Chamber: What's the Right Solution for Your Products
  • Emeritus Addresses Hospital Bed Shortages with Smart Storage Solutions
  • Fulton County & Grow Your World Amplify Atlanta Youth Through the Youth Audio Collective
  • 2026 Oscars Betting Odds: One Battle After Another Favored for Best Picture
  • Allen Field Co., Inc. Components Selected for Esko ArtiosCAD 3D Component Library
  • Thirteen Reasons Why Gyminny Kids Is San Diego's Best Gymnastics Gym
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
  • The Lashe® Announces Exclusive November Savings for Lash and Beauty Professionals
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • November is Lung Cancer Awareness Month: Screening Saves Aims to Increase Access to Lung Screenings in NC
  • Valeo Health Leads a New Era of Longevity and Preventive Health in the UAE
  • Torch Entertainment Presents The Frozen Zoo
  • Philadelphia Based Teen Singer/Songwriter and his Producer Brother Release First Single

Popular on PennZone

  • New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks - 442
  • Mensa Foundation's New Science Program Encourages Hands-On Discovery
  • Investing in Greece: Your Definitive Real-Estate FAQ Guide
  • GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
  • Blogging Pioneer Sherry Bennett Celebrates 29 Years Online - From College Blogger to Successful Entrepreneur
  • Tami Goveia Enters FabOver40, Inspiring Hollywood Legacy for Breast Cancer Cause
  • J French's #1 Album "I Don't Believe in Bad Days" Enters the Grammy Conversation
  • Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
  • 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
  • The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague

Similar on PennZone

  • 2026 NBA Mock Draft: New Wave of Franchise Talent Emerges in Early Lottery Projections
  • ReedSmith® Celebrates Innovative Founders at TCVN's Survivor™ XII at SoCal Startup Day
  • Free At Last Bail Bonds Gives Back Through Major Holiday Food Distribution Efforts Across Metro Atlanta
  • Uk Financial Ltd Provides Investors Of Maya Preferred & Mayacat Instructions For Upcoming First Ever Listing Of Both Erc-3643 "SEC-Ready" Tokens
  • Bahamas Import Assistant Launches Same-Day Pet Permit Service Under BAHFSA's 2024 Expansion
  • Liftoff Enterprises Launches Liftoff Spotlight,™ A Nationally Broadcast Platform Turning Conversations Into Revenue
  • "Meet the Eatmons" Offer Financial Advice ahead of the Holidays
  • Slotozilla's Q3 2025: SBC Lisbon Outcomes and Partnership Expansion
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us